Format

Send to

Choose Destination
AIDS Res Hum Retroviruses. 2017 Sep;33(9):929-934. doi: 10.1089/AID.2016.0327. Epub 2017 May 16.

Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.

Author information

1
1 Department of Medicine, University of Colorado Denver , Aurora, Colorado.
2
2 Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS , Rio de Janeiro, Brazil .
3
3 Les Centres GHESKIO , Port-au-Prince, Haiti .
4
4 Asociación Civil Impacta Salud y Educación , Lima, Peru .
5
5 Department of Global Health, University of Washington , Seattle, Washington.
6
6 Department of Medicine, University of Zimbabwe-College of Health Sciences , Harare, Zimbabwe .
7
7 YRGCARE Medical Centre , CART CRS, Chennai, India .
8
8 Clinical HIV Research Unit, Department of Medicine, University of Witwatersrand , Johannesburg, South Africa .
9
9 Durban International Clinical Research Site , Durban, South Africa .
10
10 College of Medicine , Blantyre, Malawi .
11
11 Department of Medicine, Johns Hopkins University , Baltimore, Maryland.

Abstract

Growth hormone (GH)/insulin-like growth factor (IGF)-1 axis abnormalities have been associated with body composition changes among HIV-infected persons with wasting or lipodystrophy. Little is known of GH/IGF-1 axis alterations with antiretroviral therapy (ART) initiation or differing ART therapies. The AIDS Clinical Trials Group Prospective Evaluation of Antiretrovirals in Resource-Limited Settings (PEARLS) study was a prospective, randomized clinical trial of ART initiation with emtricitabine/tenofovir + efavirenz (FTC/TDF+EFV) versus lamivudine/zidovudine + efavirenz (3TC/ZDV+EFV) in HIV-1-infected individuals from resource-diverse settings. IGF-1 was measured from baseline, week 48, and week 96 stored serum samples. Multivariate models were constructed. 415 participants were included: 170 (41%) were randomized to FTC/TDF+EFV and 245 (59%) to 3TC/ZDV+EFV. The mean age was 35 years, 60% were black, 42% women. The mean IGF-1 level did not change significantly from baseline to week 96 (-0.65 ng/ml; 95% confidence interval (CI) -5.18-3.87), p = .78 and there were no differences by treatment arm at week 96, p = .74. Lower baseline IGF-1 was associated with age, non-white race, greater waist-hip ratio (WHR), low CD4 count, and lower baseline albumin (all p < .01) but not plasma HIV-1 RNA, body mass index, or treatment arm. Greater change in IGF-1 from baseline to 96 weeks was associated with female sex, smaller WHR change, lower baseline albumin, and higher baseline HIV-1 RNA (all p < .01). ART initiation with either ZDV or TDF did not significantly impact overall IGF-1 levels. Baseline and on-treatment changes in IGF-1 with ART initiation may be related to the body composition changes that occur after ART initiation.

KEYWORDS:

HIV; antiretroviral therapy; highly active; insulin-like growth factor-1; lipodystrophy; obesity

PMID:
28403619
PMCID:
PMC5576217
DOI:
10.1089/AID.2016.0327
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center